Angiotensin II induces angiogenic factors production partly via AT1/JAK2/STAT3/SOCS3 signaling pathway in MHCC97H cells

Cellular Physiology and Biochemistry

Volumn 29, Issue 5-6, 2012, Pages 863-874

  Ji, Yuanyuan ^a   Wang, Zhidong ^a   Li, Zongfang ^a   Li, Ke ^a   Le, Xiaofeng ^b   Zhang, Ting ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Angiogenesis; Angiotensin II; Hepatocellular carcinoma; Janus kinase 2; Suppressor of cytokine signaling 3

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOGENIC FACTOR; ANGIOPOIETIN RECEPTOR; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; JANUS KINASE 2; LOSARTAN; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; SMALL INTERFERING RNA; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; VASCULOTROPIN;

ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84861366277     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000171034     Document Type: Article

References (53)

1. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003;362:1907-1917. (Pubitemid 37518510)
2. Izumi N, Asahina Y, Noguchi O, Uchihara M, Kanazawa N, Itakura J, Himeno Y, Miyake S, Sakai T, Enomoto N: Risk factors for distant recurrence of hepatocellular carcinoma in the liver after complete coagulation by microwave or radiofrequency ablation. Cancer 2001;91:949-956.
3. Fernandez M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J: Angiogenesis in liver disease. J Hepatol 2009;50:604-620.
4. Ke Z, Li HY, Su XL, Wang XY, Tian T, Li F, Ren GS: Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth human hepatocellular carcinoma cells. J Exp Clin Cancer Res 2010;29:31.
5. Raskopf E, Vogt A, Sauerbruch T, Schmitz V: siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo. J Hepatol 2008;49:977-984.
6. Zhang ZL, Liu ZS, Sun Q: Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma. World J Gastroenterol 2006;12:4241-4245. (Pubitemid 44376912)
7. Tanaka S, Sugimachi K, Yamashita Yi Y, Ohga T, Shirabe K, Shimada M, Wands JR, Sugimachi K: Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma. Hepatology 2002;35:861-867. (Pubitemid 34258380)
8. Torimura T, Ueno T, Kin M, Harada R, Taniguchi E, Nakamura T, Sakata R, Hashimoto O, Sakamoto M, Kumashiro R, Sata M, Nakashima O, Yano H, Kojiro M: Overexpression of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. J Hepatol 2004;40:799-807. (Pubitemid 38507361)
9. Sugimachi K, Tanaka S, Taguchi K, Aishima S, Shimada M, Tsuneyoshi M: Angiopoietin switching regulates angiogenesis and progression of human hepatocellular carcinoma. J Clin Pathol 2003;6:854-860. (Pubitemid 37386575)
10. Zhao Y, Chen X, Cai L, Yang Y, Sui G, Fu S: Angiotensin II/angiotensin II type I receptor (AT1R) signaling promotes MCF-7 breast cancer cells survival via PI3-kinase/Akt pathway. J Cell Physiol 2010;225:168-173.
11. Deshayes F, Nahmias C: Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 2005;16:293-299. (Pubitemid 41206635)
12. Neo JH, Ager EI, Angus PW, Zhu J, Herath CB, Christophi C: Change in the renin angiotensin system during the development of colorectal cancer liver metastases. BMC Cancer 2010;10:134.
13. Otake AH, Mattar AL, Freitas HC, Machado CM, Nonogaki S, Fujihara CK, Zatz R, Chammas R: Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanoma. Cancer Chemother Pharmacol 2010;66:79-87.
14. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL, Robertson JW: Do inhibitors of angiotensin-I converting enzyme protect against risk of cancer? Lancet 1998;352:179-184. (Pubitemid 28327802)
15. Yoshiji H, Noguchi R, Toyohara M, Ikenaka Y, Kitade M, Kaji K, Yamazaki M, Yamao J, Mitoro A, Sawai M, Yoshida M, Fujimoto M, Tsujimoto T, Kawaratani H, Uemura M, Fukui H: Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. J Hepatol 2009;51:315-321.
16. Yoshiji H, Noguchi R, Fukui H: RAAS inhibitors as therapeutic alternatives in the treatment of chronic liver diseases. Nippon Rinsho 2009;67:799-806.
17. Bromberg JF: Activation of STAT proteins and growth control. Bioessays 2001;23:161-169. (Pubitemid 32116649)
18. Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW: Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 2002;285:1-24. (Pubitemid 34246317)
19. Yu H, Jove R: The STATs of cancer-new molecular target come of age. Nat Rev Cancer 2004;4:97-105. (Pubitemid 38198738)
20. Huynh H: Molecularly targeted therapy in hepatocellular carcinoma. Biochem Pharmacol 2010;80:550-560.
21. Croker BA, Kiu H, Nicholson SE: SOCS regulation of the JAK/STAT signalling pathway. Semin Cell Dev Biol 2008;19:414-422.
22. Fujimoto M, Naka T: Regulation of cytokine signaling by SOCS family molecules. Trends Immunol 2003;24:659-666. (Pubitemid 37485916)
23. Riehle KJ, Campbell JS, McMahan RS, Johnson MM, Beyer RP, Bammler TK, Fausto N: Regulation of liver regeneration and hepatocarcinogenesis by suppressor of cytokine signaling 3. J Exp Med 2008;205:91-103. (Pubitemid 351185718)
24. Elliott J: SOCS3 in liver regeneration and hepatocarcinoma. Mol Interv 2008;8:19-21. (Pubitemid 351398448)
25. Khakoo AY, Sidman RL, Pasqualini R, Arap W: Does the renin-angiotensin system participate in regulation of human vasculogenesis and angiogenesis? Cancer Res 2008;68:9112-9115.
26. Wang Z, Zhou J, Fan J, Tan CJ, Qiu SJ, Yu Y, Huang XW, Tang ZY: Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma. J Cancer Res Clin Oncol 2009;135:715-722.
27. Singh RP, Dhanalakshmi S, Agarwal C, Agarwal R: Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NFkappaB: implications for angioprevention and antiangiogenic therapy. Oncogene 2005;24:1188-1202. (Pubitemid 40313920)
28. Ji YY, Liu JT, Wang ZD, Liu N: Angiotensin II induces inflammatory response partly via toll-like receptor 4-dependent signaling pathway in vascular smooth muscle cells. Cell Physiol Biochem 2009;23:265-276.
29. Roskoski R Jr: Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 2007;62:179-213. (Pubitemid 46679285)
30. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364. (Pubitemid 26272076)
31. Mise M, Arii S, Higashituji H, Furutani M, Niwano M, Harada T, Ishigami S, Toda Y, Nakayama H, Fukumoto M, Fujita J, Imamura M: Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology 1996;23:455-464. (Pubitemid 26087158)
32. Dhar DK, Naora H, Yamanoi A, Ono T, Kohno H, Otani H, Nagasue N: Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: a comparison with angiopoietin/Tie pathway. Anticancer Res 2002;22:379-386. (Pubitemid 34475326)
33. Torimura T, Sata M, Ueno T, Kin M, Tsuji R, Suzaku K, Hashimoto O, Sugawara H, Tanikawa K: Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol 1998;29:986-991. (Pubitemid 28422048)
34. Kaseb AO, Hanbali A, Cotant M, Hassan MM, Wollner I, Philip PA: Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature. Cancer 2009;115:4895-4906.
35. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, Yancopoulos GD: Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996;87:1161-1169. (Pubitemid 27010100)
36. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997;277:55-60. (Pubitemid 27450643)
37. Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR: Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 1999;103:341-345. (Pubitemid 29069983)
38. Mitsuhashi N, Shimizu H, Ohtsuka M, Wakabayashi Y, Ito H, Kimura F, Yoshidome H, Kato A, Nukui Y, Miyazaki M: Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology 2003;37:1105-1113. (Pubitemid 36538687)
39. Kuboki S, Mitsuhashi N, Kusashio K, Kimura F, Yoshidome H, Ohtsuka M, Kato A, Yoshitomi H, Miyazaki M: Angiopoietin-2 levels in the hepatic vein as a useful predictor of tumor invasiveness and prognosis in human hepatocellular carcinoma. J Gastroenterol Hepatol 2008;23:e157-e164. (Pubitemid 352019432)
40. Olsen MW, Ley CD, Junker N, Hansen AJ, Lund EL, Kristjansen PE: Angiopoietin-4 inhibits angiogenesis and reduces interstitial Xuid pressure. Neoplasia 2006;8:364-372. (Pubitemid 43830743)
41. Brown JL, Cao ZA, Pinzon-Ortiz M, Kendrew J, Reimer C, Wen S, Zhou JQ, Tabrizi M, Emery S, McDermott B, Pablo L, McCoon P, Bedian V, Blakey DC: A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol Cancer Ther 2010;9:145-156.
42. Yuan HT, Khankin EV, Karumanchi SA, Parikh SM: Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol 2009;29:2011-2022.
43. Heffelfinger SC: The renin angiotensin system in the regulation of angiogenesis. Curr Pharm Des 2007;13:1215-1229. (Pubitemid 46739330)
44. Kondyli M, Gatzounis G, Kyritsis A, Varakis J, Assimakopoulou M: Immunohistochemical detection of phosphorylated JAK-2 and STAT-5 proteins and correlation with erythropoietin receptor (EpoR) expression status in human brain tumors. J Neurooncol 2010;100:157-164.
45. Ihle JN: STATs: signal transducers and activators of transcription. Cell 1996;84:331-334. (Pubitemid 26058558)
46. Chen SH, Murphy DA, Lassoued W, Thurston G, Feldman MD, Lee WM: Activated STAT3 is a mediator and biomarker of VEGF endothelial activation. Cancer Biol Ther 2008;7:1994-2003.
47. Frank DA: STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett 2007;251:199-210. (Pubitemid 46680370)
48. Knoops L, Hornakova T, Royer Y, Constantinescu SN, Renauld JC: JAK kinases overexpression promotes in vitro cell transformation. Oncogene 2008;27:1511-1519. (Pubitemid 351347883)
49. Buettner R, Mora LB, Jove R: Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002;8:945-954. (Pubitemid 35177340)
50. Dzau VJ, Mukoyama M, Pratt RE: Molecular biology of angiotensin receptors: target for drug research? J Hypertens Suppl 1994;12:S1-S5. (Pubitemid 24212087)
51. Fujita M, Hayashi I, Yamashina S, Fukamizu A, Itoman M, Majima M: Angiotensin type 1a receptor signalingdependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 2005;26:271-279. (Pubitemid 40253497)
52. Kandalam U, Clark MA: Angiotensin II activates JAK2/STAT3 pathway and induces interleukin-6 production in cultured rat brainstem astrocytes. Regul Pept 2010;159:110-116.
53. Ogata H, Kobayashi T, Chinen T, Takaki H, Sanada T, Minoda Y, Koga K, Takaesu G, Maehara Y, Iida M, Yoshimura A: Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitisinduced hepatocarcinogenesis. Gastroenterology 2006;131:179-193. (Pubitemid 44015756)